Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia

Pharmacotherapy

Volumn 28, Issue 2, 2008, Pages 281-284

  Saadeh, Claire E ^a,b,d   Srkalovic, Gordan ^b,c  

^a FERRIS STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d Michigan State University and Sparrow Health System   (United States)

Author keywords

Alemtuzumab; B CLL; Chronic lymphocytic leukemia; Infectious complications; MAC; Mycobacterium avium complex

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETHAMBUTOL; FAMCICLOVIR; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RITUXIMAB;

ADULT; ARTICLE; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CYTOMEGALOVIRUS; HERPES SIMPLEX VIRUS; HUMAN; INFECTION SENSITIVITY; LYMPHOCYTOPENIA; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NEUTROPENIA; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS JIROVECI;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOCOMPROMISED HOST; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; OPPORTUNISTIC INFECTIONS; TUBERCULOSIS, LYMPH NODE;

EID: 38849130027     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.2.281     Document Type: Article

References (18)

1. Thursky KA, Worth LJ, Seymour JF, Prince HM, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006;132(1):3-12.
2. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006;43(1):16-24.
3. Abad S, Gyan E, Moachon L, et al. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration [online exclusive article]. Clin Infect Dis 2003;37(2):e27-8. Available from http://www.journals. uchicago.edu/CID/journal/issues/v37n2/30481/30481.html.
4. Ravandi F, O'Brien S. Alemtuzumab. Expert Rev Anticancer Ther 2005;5(1):39-51.
5. Genzyme Corporation. Campath (alemtuzumab) package insert. Cambridge, MA; 2005.
6. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004;18(3):484-90.
7. Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol 2006;33(2):240-9.
8. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20(18):3891-7.
9. Wendtner CM, Ritgen M, Schweighofer CD, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission: experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL study group (GCLLSG). Leukemia 2004;18(6):1093-101.
10. Ferrajoli A, O'Brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003;98(4):773-8.
11. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103(8):2920-4.
12. Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European study group of CAMPATH-1H treatment in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1998;16(10):3257-63.
13. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101(11):4267-72.
14. Weinblatt ME, Maddison PJ, Bulpitt KJ, et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis: an intravenous dose-escalation study. Arthritis Rheum 1995;38(11):1589-94.
15. Issacs JD, Greer S, Sharma S, et al. Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum 2001;44(9):1998-2008.
16. Basu A, Ramkumar M, Tan HP, et al. Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc 2005;37(2):923-6.
17. Calne R, Moffatt SD, Friend PJ, et al. Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999;68(10):1613-16.
18. D'Sa S, Peggs K, Pizzey A, et al. T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions. Br J Haematol 2003;123(2):309-22.